FDA 483 - Immunologix Laboratories - September 12, 2025

An FDA inspection of Immunologix Laboratories in Tampa, FL, a nonclinical laboratory, identified one observation. The primary concern was the failure of the study director to ensure proper archiving of raw data and documentation for bioanalytical studies. This indicates a significant issue with data integrity and record-keeping practices.